摘要
目的探讨AECOPD患者联用噻托溴铵和大剂量布地奈德的作用。方法将78例AECOPD患者平均分为常规组(大剂量布地奈德+常规支持治疗)、联合组(噻托溴铵+常规组方案)。对比两组血气指标、效果和安全性。结果治疗后,两组患者的PaO_2和SaO_2均升高,差异具有统计学意义(P<0.05),联合组更高,差异具有统计学意义(P<0.05);治疗后,两组患者的PaCO_2均降低,差异具有统计学意义(P<0.05),联合组更低,差异具有统计学意义(P<0.05);两组患者的总有效率比较,差异具有统计学意义(P<0.05);两组患者的不良反应发生率对比,差异不具有统计学意义(P>0.05)。结论对AECOPD联用噻托溴铵、大剂量布地奈德作用理想,安全可靠。
Objective To investigate the effect of combined use of Tiotropium bromide and high-dose budesonide in patients with AECOPD. Methods 78 cases of AECOPD patients were equally divided into the routine group （high-dose budesonide ＋ conventional supportive therapy） and the combined group （tiotropium ＋ routine regimen）. The blood gas indexes, effects and safety of the two groups were compared. Results After treatment, the PaO2 and SaO2 of the two groups were increased, the diference was statistically signifcant （P 〈 0.05）, the combined group was higher, the diference was statistically signifcant （P 〈 0.05）. After treatment, the PaCO2 of the two groups decreased, the difference was statistically signifcant （P 〈 0.05）, the combined group was lower, the diference was statistically signifcant （P 〈 0.05）. The total efective rate of the two groups was statistically signifcant （P 〈 0.05）. There was no signifcant diference in the incidence of adverse reactions between the two groups （P 〉 0.05）. Conclusion The efect of AECOPD combined with tiotropium bromide and high-dose budesonide is ideal, safe and reliable.
出处
《中国继续医学教育》
2018年第26期128-129,共2页
China Continuing Medical Education
关键词
噻托溴铵
布地奈德
慢性阻塞性肺疾病
血气指标
临床效果
安全性
tiotropium bromide
budesonide
chronic obstructive pulmonary disease
blood gas index
clinical efcacy
safety
